PD
PDC.F MEDNAX Inc
- Market cap
- EUR 2.20B
- P/E
- 17.8x
- P/B
- 2.85x
- ROE
- 18.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PDC.F undervalued?
Graham numberPDC.F trades 50.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEDNAX Inc fundamental analysis
No fundamental analysis for MEDNAX Inc yet.
MEDNAX Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEDNAX Inc
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to…
Full company profileMEDNAX Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MEDNAX Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.18B | 3.46B | 3.65B | 3.51B | 1.73B | 1.91B | 1.97B | 1.99B | 2.01B | 1.91B | 1.95B |
| Gross Profit | 1.03B | 1.00B | 990M | 892M | 449M | 513M | 467M | 422M | 454M | 494M | 514M |
| Operating Income | 572M | 480M | 446M | 408M | 172M | 218M | 200M | 158M | 184M | 231M | 244M |
| EBITDA | - | 588M | 569M | -1.04B | 146M | 236M | 157M | 29.9M | -28.4M | 274M | 267M |
| Net Income | 325M | 320M | 269M | -1.50B | -796M | 131M | 66.3M | -60.4M | -99.1M | 165M | 155M |
| EPS | - | 3.42 | 3.06 | -18 | -9.31 | 1.52 | 0.80 | -0.72 | -1.15 | 1.99 | 1.99 |
| Balance Sheet | |||||||||||
| Total Assets | 5.34B | 5.87B | 5.93B | 4.15B | 3.35B | 2.72B | 2.35B | 2.22B | 2.15B | 2.25B | 2.14B |
| Total Liabilities | 2.58B | 2.80B | 2.85B | 2.65B | 2.60B | 1.83B | 1.46B | 1.37B | 1.39B | 1.38B | 1.29B |
| Shareholders' Equity | 2.76B | 3.07B | 3.09B | 1.50B | 747M | 896M | 892M | 849M | 765M | 866M | 850M |
| Cash & Short-term Investments | 55.7M | 60.2M | 36.7M | 113M | 1.12B | 387M | 9.82M | 73.3M | 230M | 375M | 312M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 444M | 498M | 314M | 358M | 205M | 76.7M | 167M | 167M | 207M | 271M | 150M |
| Capital Expenditure | 39.3M | 26.2M | 17.1M | 19.3M | 28.8M | 32.2M | 29.7M | 33.3M | 22.0M | 18.5M | 16.0M |
| Free Cash Flow | - | 462M | 241M | 315M | 176M | 44.5M | 137M | 133M | 185M | 253M | 134M |
| Ratios | |||||||||||
| ROE | 11.8% | 10.4% | 8.7% | -99.9% | -106.6% | 14.6% | 7.4% | -7.1% | -13.0% | 19.1% | 18.3% |
| ROA | 6.1% | 5.5% | 4.5% | -36.1% | -23.8% | 4.8% | 2.8% | -2.7% | -4.6% | 7.4% | 7.3% |
| Net Profit Margin | 10.2% | 9.3% | 7.4% | -42.6% | -45.9% | 6.9% | 3.4% | -3.0% | -4.9% | 8.6% | 7.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MEDNAX Inc dividends
MEDNAX Inc has not paid dividends in the last 9 fiscal years.
Who owns MEDNAX Inc
- Insiders 2.12%
- Institutions 97.89%
- Public & others 0.00%
- Shares outstanding 78.1M
- Free float 74.9M
MEDNAX Inc company profile
- Company name
- MEDNAX Inc
- Ticker
- PDC.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 4,280
- Fiscal year end
- December
- Address
- 1301 Concord Terrace, Sunrise, FL, United States, 33323
- Phone
- 954 384 0175
- Website
- pediatrix.com
About MEDNAX Inc
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
MEDNAX Inc management
10- Mr. Mark S. OrdanCEO & Executive Chairman · born 1959
- Ms. Kasandra H. RossiExecutive VP, Treasurer & CFO · born 1973
- Mr. D. Gregory NeebExecutive VP & Chief Operating and Strategy Officer · born 1968
- Mr. John C. PepiaSenior VP & Chief Accounting Officer · born 1963
- Ms. Cheryl M. VanPattenSenior VP & Chief Information Officer
- Mr. David HaddockExecutive Vice President, General Counsel & Secretary
- Ms. Debra McRobertsSenior Vice President of People Services
- Mr. Kevin PitzerPresident of West Division
- Mr. Mike AshfordPresident of South Central Division
- Dr. Michael Dwyer M.D.Chief Medical Officer of South Central Division